RMAM
NKTR icon

Raab & Moskowitz Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-37
Closed -$9K – 291
2014
Q4 		$9K Buy
+37
New +$7.91K 0.01% 347

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raab & Moskowitz Asset Management's NKTR Position: Q1 2015 in Review

Raab & Moskowitz Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2015, closing a stake of 37 shares — an estimated $9K sold.

Raab & Moskowitz Asset Management first reported a position in NKTR in Q4 2014 and held it in 1 quarter. The position peaked at $9K in Q4 2014. 153 funds tracked by Wall St. Rank hold NKTR as of Q1 2015.

  • Raab & Moskowitz Asset Management reported no remaining Nektar Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Raab & Moskowitz Asset Management sold 37 Nektar Therapeutics shares in Q1 2015, an estimated $9K.
  • Raab & Moskowitz Asset Management first reported a position in Nektar Therapeutics in Q4 2014 and held it in 1 quarter.
  • Raab & Moskowitz Asset Management's Nektar Therapeutics position peaked at $9K in Q4 2014.
  • 153 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2015.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2015, filed 12 May 2015.